Bridge City Capital’s Emergent Biosolutions EBS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-39,835
Closed -$1.64M 93
2022
Q1
$1.64M Sell
39,835
-17,034
-30% -$751K 0.76% 68
2021
Q4
$2.47M Buy
56,869
+19,027
+50% +$861K 1.02% 43
2021
Q3
$1.9M Buy
37,842
+1,452
+4% +$87.9K 0.86% 62
2021
Q2
$2.29M Sell
36,390
-1,235
-3% -$79.3K 0.78% 65
2021
Q1
$3.5M Buy
+37,625
New +$3.85M 1.16% 39

Other funds holding EBS

Bridge City Capital's EBS Position: Q2 2022 in Review

Bridge City Capital sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 39,835 shares — an estimated $1.64M sold.

Bridge City Capital first reported a position in EBS in Q1 2021 and held it in 5 quarters. The position peaked at $3.5M in Q1 2021. 232 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

  • Bridge City Capital reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
  • Bridge City Capital sold 39,835 Emergent Biosolutions shares in Q2 2022, an estimated $1.64M.
  • Bridge City Capital first reported a position in Emergent Biosolutions in Q1 2021 and held it in 5 quarters.
  • Bridge City Capital's Emergent Biosolutions position peaked at $3.5M in Q1 2021.
  • 232 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Bridge City Capital's 13F filing for Q2 2022, filed 15 Aug 2022.